Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 2/20 | 0.54 |
| ▸ | TACR1 | P25103 | 3/20 | 0.52 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.51 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.50 |
| ▸ | JAK2 | O60674 | 1/20 | 0.49 |
| ▸ | JAK1 | P23458 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.48 |
| ▸ | USP7 | Q93009 | 2/20 | 0.47 |
| ▸ | STS | P08842 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7906244 | 1.00 | RORC (0.54) | RORCTACR1GPR119PDE4BJAK2 | |
| SCHEMBL3010008 | 1.00 | RORC (0.54) | RORCTACR1GPR119PDE4BJAK2 | |
| SCHEMBL16108769 | 0.90 | TACR1 (0.54) | RORCTACR1GPR119PDE4BJAK2 | |
| SCHEMBL4710562 | 0.90 | TACR1 (0.54) | RORCTACR1GPR119PDE4BJAK2 | |
| SCHEMBL4709680 | 0.90 | TACR1 (0.54) | RORCTACR1GPR119PDE4BJAK2 | |
| SCHEMBL16141295 | 0.90 | TACR1 (0.54) | RORCTACR1GPR119PDE4BJAK2 | |
| SCHEMBL2343146 | 0.89 | RORC (0.60) | RORCTACR1GPR119PDE4BKDM4E | |
| SCHEMBL4007683 | 0.89 | RORC (0.60) | RORCTACR1GPR119PDE4BKDM4E | |
| SCHEMBL13809297 | 0.89 | RORC (0.60) | RORCTACR1GPR119PDE4BKDM4E | |
| SCHEMBL4247036 | 0.89 | RORC (0.60) | RORCTACR1GPR119PDE4BKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2391615-B1 | PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2013-01-16 | — | — | EP | disclosed |
| US-8324248-B2 | Piperidine derivatives as NK3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-12-04 | — | — | US | disclosed |
| CN-102282139-A | Piperidine derivatives as nk3 receptor antagonists | — | 2011-12-14 | — | — | CN | disclosed |
| EP-2391615-A1 | Piperidine derivatives as nk3 receptor antagonists | F. Hoffmann-La Roche AG (CH) | 2011-12-07 | — | — | EP | disclosed |
| US-20100197697-A1 | PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-08-05 | — | — | US | disclosed |
| WO-2010086259-A1 | PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197697-A1 | PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | OPRK1, OPRM1, OPRL1 | RORC 1038/4885TACR1 13/4885GPR119 648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.